Title |
MRl of Prostate Cancer Antigen Expression for Diagnosis and lmmunotherapy
|
---|---|
Published in |
PLOS ONE, June 2012
|
DOI | 10.1371/journal.pone.0038350 |
Pubmed ID | |
Authors |
Jing Ren, Fang Wang, Guangquan Wei, Yong Yang, Ying Liu, Mengqi Wei, Yi Huan, Andrew C. Larson, Zhuoli Zhang |
Abstract |
Tumor antigen (TA)-targeted monoclonal antibody (mAb) immunotherapy can be effective for the treatment of a broad range of cancer etiologies; however, these approaches have demonstrated variable clinical efficacy for the treatment of patients with prostate cancer (PCa). An obstacle currently impeding translational progress has been the inability to quantify the mAb dose that reaches the tumor site and binds to the targeted TAs. The coupling of mAb to nanoparticle-based magnetic resonance imaging (MRI) probes should permit in vivo measurement of patient-specific biodistributions; these measurements could facilitate future development of novel dosimetry paradigms wherein mAb dose is titrated to optimize outcomes for individual patients. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Denmark | 1 | 3% |
Unknown | 39 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 8 | 20% |
Researcher | 8 | 20% |
Other | 5 | 13% |
Student > Master | 5 | 13% |
Student > Bachelor | 3 | 8% |
Other | 7 | 18% |
Unknown | 4 | 10% |
Readers by discipline | Count | As % |
---|---|---|
Chemistry | 7 | 18% |
Biochemistry, Genetics and Molecular Biology | 6 | 15% |
Medicine and Dentistry | 6 | 15% |
Engineering | 3 | 8% |
Agricultural and Biological Sciences | 2 | 5% |
Other | 7 | 18% |
Unknown | 9 | 23% |